Physician profile
Dina Green
NPI 1669404869
$15,938.31
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,580 · 2020: $2,725 · 2021: $2,615 · 2022: $2,521 · 2023: $2,829 · 2024: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,496.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,550.69 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,287.37 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,543.34 | 2019-2024 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $1,082.25 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $1,020.64 | 2019-2023 | Steglatro |
| Dexcom, INC. | $964.79 | 2020-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $697.51 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $598.22 | 2020-2024 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $563.85 | 2019-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $517.49 | 2019-2021 | |
| Abbvie INC. | $515.96 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $490.73 | 2019-2024 | Cycloset |
| Amarin Pharma, INC. | $483.00 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $326.12 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $210.25 | 2019-2020 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $181.70 | 2019-2024 | |
| Medtronic, INC. | $180.15 | 2021-2023 | Minimed 770g |
| Radius Health, INC. | $170.23 | 2019-2020 | |
| Medtronic Minimed, INC. | $146.98 | 2019-2020 | |
| Ibsa Pharma INC. | $143.42 | 2019-2024 | Tirosint, Licart, Tirosint |
| Insulet Corporation | $135.82 | 2019-2024 | Omnipod |
| Alexion Pharmaceuticals, INC. | $107.76 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $89.36 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Companion Medical, INC. | $84.74 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.67 | 2023-2024 | |
| Becton, Dickinson and Company | $81.68 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $80.43 | 2019 | |
| Corcept Therapeutics | $64.55 | 2019-2022 | |
| Shire North American Group INC | $61.01 | 2019 | |
| Eisai INC. | $52.53 | 2019 | |
| Cequr Corporation | $47.93 | 2022-2024 | Cequr Simplicity |
| Ipsen Biopharmaceuticals, INC | $39.40 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $29.99 | 2020 | |
| Angiodynamics, INC. | $28.60 | 2023 | Auryon Laser System 100-120 Vac |
| Lifescan, INC. | $28.54 | 2020-2021 | |
| Ascensia Diabetes Care US INC. | $28.09 | 2024 | |
| Zealand Pharma US, INC. | $25.97 | 2020 | |
| Currax Pharmaceuticals LLC | $24.15 | 2019-2020 | |
| Beta Bionics, INC. | $23.66 | 2023 | Ilet Bionic Pancreas |
| Horizon Therapeutics Plc | $18.83 | 2020 | |
| Nevro Corp. | $18.76 | 2023 | Senza |
| Bigfoot Biomedical INC | $17.11 | 2021 | |
| Embecta Corp. | $16.92 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Averitas Pharma INC. | $16.55 | 2023 | Qutenza |
| Kyowa Kirin, INC. | $16.49 | 2023 | Crysvita |
| Tolmar, INC. | $15.33 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.94 | 2020 | |
| Ferring Pharmaceuticals INC. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.